What's in UMC Utrecht's pipeline?

UMC Utrecht has 38 drugs in our index: 10 marketed, 0 filed, 21 in Phase 3, 2 in Phase 2, 5 in Phase 1.

Which companies overlap with UMC Utrecht's portfolio?

Top competitors by shared drug class: Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, University of Oxford, Hoffmann-La Roche.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/umc-utrecht.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

UMC Utrecht — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

UMC Utrecht pipeline: 10 marketed, 0 filed, 21 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

10 marketed 0 filed 21 Phase 3 2 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Progesterone Vaginal Product	Progesterone Vaginal Product	marketed	Progestin	Progesterone receptor (PR)	Reproductive Health / Obstetrics
Aripiprazole depot	Aripiprazole depot	marketed
Rivastigmine Transdermal Product	Rivastigmine Transdermal Product	marketed
Mild stimulation	Mild stimulation	marketed	Stimulant		Neurology
aspirin and dipyridamole	aspirin and dipyridamole	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]
Intermediate dose thromboprophylaxis	Intermediate dose thromboprophylaxis	marketed	Anticoagulant (dosing strategy)		Cardiovascular
Sevoflurane and isoflurane	Sevoflurane and isoflurane	marketed
aspirin alone	aspirin alone	marketed
All registered antiepileptic drugs	All registered antiepileptic drugs	marketed	Antiepileptic drugs (heterogeneous class)	Multiple targets including voltage-gated sodium channels, GABA receptors, calcium channels, SV2A, and others depending on specific agent	Neurology
simvastatin and ezetimibe	simvastatin and ezetimibe	marketed	Statin and cholesterol absorption inhibitor combination	HMG-CoA reductase and NPC1L1 transporter	Cardiovascular
Nirmatrelvir/ritonavir + remdesivir	Nirmatrelvir/ritonavir + remdesivir	phase 3	Antiviral combination (protease inhibitor + nucleotide analog)	SARS-CoV-2 3CL protease; SARS-CoV-2 RNA-dependent RNA polymerase	Infectious Disease / Virology
Extended course macrolide	Extended course macrolide	phase 3	Macrolide antibiotic (anti-inflammatory/immunomodulatory use)		Respiratory/Pulmonology

Therapeutic area mix

Cardiovascular · 8
Infectious Disease / Virology · 3
Infectious Disease · 2
Neurology · 2
Infectious Diseases · 2
Immunology/Infectious Disease · 1
Critical Care · 1
Infectious disease · 1
Oncology; Infectious Disease; Inflammation Imaging · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 5 shared drug classes
GlaxoSmithKline · 4 shared drug classes
Bristol-Myers Squibb · 4 shared drug classes
University of Oxford · 3 shared drug classes
Hoffmann-La Roche · 3 shared drug classes
Teva Branded Pharmaceutical Products R&D, Inc. · 3 shared drug classes
· 3 shared drug classes
University of Utah · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for UMC Utrecht:

Cite this brief

Drug Landscape (2026). UMC Utrecht — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/umc-utrecht. Accessed 2026-06-10.